Blood coagulation factor X: molecular biology, inherited disease, and engineered therapeutics | Zendy

Rodney M. Camire | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Blood coagulation factor X: molecular biology, inherited disease, and engineered therapeutics

Author(s) -

Rodney M. Camire

Publication year - 2021

Publication title -

journal of thrombosis and thrombolysis

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.708

H-Index - 67

eISSN - 1573-742X

pISSN - 0929-5305

DOI - 10.1007/s11239-021-02456-w

Subject(s) - coagulation , coagulation cascade , medicine , hematology , thrombin , clotting factor , factor ix , blood clotting , computational biology , thrombin generation , prothrombinase , bioinformatics , immunology , biology , platelet

Blood coagulation factor X/Xa sits at a pivotal point in the coagulation cascade and has a role in each of the three major pathways (intrinsic, extrinsic and the common pathway). Due to this central position, it is an attractive therapeutic target to either enhance or dampen thrombin generation. In this brief review, I will summarize key developments in the molecular understanding of this critical clotting factor and discuss the molecular basis of FX deficiency, highlight difficulties in expressing recombinant factor X, and detail two factor X variants evaluated clinically.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research